Table 2 Baseline characteristics among breast cancer subtypes, n(%)
Variables | Total | Cohort 1 | Cohort 2 | P-valuea |
|---|---|---|---|---|
Number of patients | 3868 | 1485 | 2383 | |
Age (year) | < 0.001 | |||
< 40 | 445 (11.4) | 204 (13.8) | 241 (10.1) | |
40–60 | 2589 (67.0) | 1028 (69.2) | 1561 (65.5) | |
> 60 | 834 (21.6) | 253 (17.0) | 581 (24.4) | |
Stage | < 0.001 | |||
I | 586 (15.1) | 206 (13.9) | 380 (15.9) | |
II | 1553 (40.1) | 621 (41.8) | 932 (39.1) | |
III | 831 (21.5) | 275 (18.5) | 556 (23.4) | |
IV | 265 (6.8) | 97 (6.5) | 168 (7.0) | |
Unknown | 633 (16.4) | 286 (19.2) | 347 (14.6) | |
Chemotherapy | < 0.001 | |||
No | 1178 (30.4) | 399 (26.9) | 779 (32.7) | |
Yes | 2690 (69.5) | 1086 (73.1) | 1604 (67.3) | |
Chemotherapy Regimens | < 0.001 | |||
CMF | 161 (6.0) | 142 (13.1) | 19 (1.2) | |
FAC/FEC/AC | 1930 (71.7) | 840 (77.4) | 1090 (67.9) | |
AC-T | 599 (22.3) | 104 (9.6) | 495 (30.9) | |
Radiotherapy | 0.03 | |||
No | 1794 (46.4) | 722 (48.6) | 1072 (45.0) | |
Yes | 2074 (53.6) | 763 (51.4) | 1311 (55.0) | |
Hormonal therapy | < 0.001 | |||
No | 1772 (45.8) | 770 (51.8) | 1002 (42.0) | |
Yes | 2096 (54.2) | 715 (48.1) | 1381 (58.0) | |
Hormonal therapy agent | < 0.001 | |||
Tamoxifen | 1335 (75.2) | 583 (86.6) | 752 (68.3) | |
Aromatase Inhibitor | 439 (24.8) | 90 (13.4) | 349 (31.7) | |